The trajectory of companies tied to Sildenafil's legacy presents a intricate investment landscape. While the initial surge generated substantial profits , generic alternatives have significantly diminished market share . Investing in related pharmaceutical companies now requires a thorough assessment of patent safeguards, evolving patient shifts ,